The announcement of positive results from a clinical study, especially in a high-impact field like cancer treatment, is typically seen as a strong positive catalyst for a biotech company's stock. Given that the data was presented at a reputable conference (ASCO), this adds credibility and visibility to the findings, which can further drive investor interest and potentially lead to stock price increases in the short term.